Vaccines Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type, Indication, Route of Administration, Age Group, and Geography

Description

List of Tables

The vaccines market size is expected to grow from US$ 80.45 billion in 2024 to US$ 118.94 billion by 2031; it is projected to register a CAGR of 5.7% during 2025-2031. The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives are noteworthy factors contributing to the expansion of the vaccines market size. However, the high vaccine development cost and increased time to market hinder the vaccines market growth.

Artificial intelligence (AI) and machine learning are reshaping the landscape of vaccine research and development by introducing innovative methodologies that enhance speed and accuracy. One of the most critical applications of AI is in the analysis of complex genomic and immunological data. This technology enables researchers to rapidly identify potential vaccine targets by sifting through vast amounts of data-a process that would have traditionally taken years to accomplish. The ability to predict immune responses to these targets is particularly revolutionary, providing insights to design vaccines in a much shorter timeframe.

The strategic value of AI was evident during the COVID-19 pandemic, where it played a critical role in accelerating mRNA vaccine development clinical trials timelines, enabling companies to move from viral genome sequencing to regulatory approval within a year. In 2021, Pfizer leveraged an advanced AI-driven platform, SDQ, to streamline clinical data processing. This machine learning tool reduced the time required to clean and analyze trial data from over 30 days to just 22 hours after reaching efficacy milestones, significantly enhancing operational efficiency and speed to market.

In the manufacturing arena, the implementation of AI significantly enhances production efficiency. AI systems can streamline various stages of the production process, enhance quality control by monitoring and identifying deviations from expected standards, and forecast potential bottlenecks that could delay vaccine delivery. This proactive approach not only speeds up the production timeline but also ensures that vaccines are manufactured with a higher degree of reliability. In March 2025, Los Alamos announced that the scientists in Los Alamos National Laboratory are combining experimental data and AI for accelerating vaccine and drug development. The RAPTER vaccine development project is leveraging AI and experimental studies to expedite traditional research methods. It aims to create a predictive tool that analyzes pathogen genetic sequences and identifies effective vaccine options for rapid outbreak responses. The team is developing this tool using AI-based knowledge extraction, mechanistic modeling, and in vitro and in vivo experiments to test promising candidates. Initially, RAPTER will focus on three pathogens: SARS-CoV-2, Ebola virus, and Burkholderia pseudomallei, the bacterium that causes melioidosis, deemed a significant biological threat.

Overall, the integration of AI and machine learning into vaccine development processes is making this critical field more efficient, scalable, and adaptable to the rapidly evolving landscape of global health threats, ultimately contributing to more effective public health responses. This is expected to contribute to the growth of the vaccines market in the coming years.

Age Group -Based Insights

Based on age group, the vaccines market is segmented into pediatric and adult. The pediatric segment held the largest vaccines market share in 2024. Pediatric vaccines are immunizations given during infancy and childhood to protect against infectious diseases that pose significant risks in early life. These vaccines are typically scheduled in national immunization programs and include protection against diseases such as diphtheria, pertussis, tetanus (DTP), polio, rotavirus, measles, mumps, rubella (MMR), hepatitis B, pneumococcal, and more. This segment continues to grow due to rising awareness about early childhood immunity, increased global coverage efforts by organizations, and strong government mandates in both developed and developing countries. The burden of vaccine-preventable diseases in infants and the long-term health and economic benefits of early immunization have led to sustained policy and funding support. Combination vaccines that reduce the number of injections (e.g., pentavalent or hexavalent) and newer additions like HPV and malaria vaccines for children have further expanded the pediatric portfolio. Advances in vaccine technology, such as thermostable and needle-free delivery systems, also support outreach in low-resource areas, thereby fueling the vaccines market growth.

The World Health Organization and UNICEF are among the primary and secondary sources referred to while preparing the vaccines market report.

Product Code: TIPRE00015468

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Vaccines Market - Key Market Dynamics

5.1 Vaccines Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Growing Incidences of Infectious Diseases and Disease Outbreaks
- 5.2.2 Surging Immunization Programs and Government Initiatives
5.3 Market Restraints
- 5.3.1 High Vaccine Development Cost and Increased Time to Market
5.4 Market Opportunities
- 5.4.1 Development of Combination and Therapeutic Vaccines
5.5 Future Trends
- 5.5.1 Integration of Artificial Intelligence and Big Data in Vaccine Development
5.6 Impact of Drivers and Restraints:

6. Vaccines Market - Global Market Analysis

6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2031

7. Vaccines Market - Revenue Analysis (USD Million) - By Technology, 2020-2031

7.1 Overview
7.2 Live Attenuated Vaccines
- 7.1.1 Overview
- 7.1.2 Live Attenuated Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Inactivated Vaccines and Subunit Vaccines
- 7.2.1 Overview
- 7.2.2 Inactivated Vaccines and Subunit Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Toxoid Vaccines
- 7.3.1 Overview
- 7.3.2 Toxoid Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Conjugate Vaccines
- 7.3.1 Overview
- 7.3.2 Conjugate Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Recombinant Vaccines
- 7.3.1 Overview
- 7.3.2 Recombinant Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Others

8. Vaccines Market - Revenue Analysis (USD Million) - By Disease Indication, 2020-2031

8.1 Overview
8.2 Influenza
- 8.1.1 Overview
- 8.1.2 Influenza: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Dengue
- 8.1.1 Overview
- 8.1.2 Dengue: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Cytomegalovirus (CMV)
- 8.1.1 Overview
- 8.1.2 Cytomegalovirus (CMV): Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Hepatitis
- 8.1.1 Overview
- 8.1.2 Hepatitis: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Respiratory Synical Virus (RSV)
- 8.1.1 Overview
- 8.1.2 Respiratory Synical Virus (RSV): Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Other Diseases
- 8.1.1 Overview
- 8.1.2 Other Diseases: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

9. Vaccines Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2031

9.1 Overview
9.2 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Injectable
- 9.1.1 Overview
- 9.1.2 Injectable: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Other Route of Administration
- 9.1.1 Overview
- 9.1.2 Other Route of Administration: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

10. Vaccines Market - Revenue Analysis (USD Million) - By Patient Type, 2020-2031

10.1 Overview
10.2 Pediatric
- 10.2.1 Overview
- 10.2.2 Pediatric: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Adult
- 10.3.1 Overview
- 10.3.2 Adult: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

11. Vaccines Market - Revenue Analysis (USD Million), 2020-2031 - Geographical Analysis

11.1 North America
- 11.1.1 North America Vaccines Market Overview
- 11.1.2 North America Vaccines Market Revenue and Forecasts to 2031
- 11.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
- 11.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Disease Indication
- 11.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
- 11.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Patient Type
- 11.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Vaccines Market
    - 11.1.7.1.1 United States Vaccines Market, by Technology
    - 11.1.7.1.2 United States Vaccines Market, by Disease Indication
    - 11.1.7.1.3 United States Vaccines Market, by Route of Administration
    - 11.1.7.1.4 United States Vaccines Market, by Patient Type
  - 11.1.7.2 Canada Vaccines Market
    - 11.1.7.2.1 Canada Vaccines Market, by Technology
    - 11.1.7.2.2 Canada Vaccines Market, by Disease Indication
    - 11.1.7.2.3 Canada Vaccines Market, by Route of Administration
    - 11.1.7.2.4 Canada Vaccines Market, by Patient Type
  - 11.1.7.3 Mexico Vaccines Market
    - 11.1.7.3.1 Mexico Vaccines Market, by Technology
    - 11.1.7.3.2 Mexico Vaccines Market, by Disease Indication
    - 11.1.7.3.3 Mexico Vaccines Market, by Route of Administration
    - 11.1.7.3.4 Mexico Vaccines Market, by Patient Type
11.2 Europe
- 10.2.1 Europe Vaccines Market Overview
- 10.2.2 Europe: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.2.2.1 Europe: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.2.2.2 Europe: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.2.2.3 Europe: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.2.2.4 Europe: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.2.2.5 Europe: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.2.2.6 Europe: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.2.3 Europe: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 Germany: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.1.1 Germany: Vaccines Market Breakdown, by Technology
    - 10.2.3.1.2 Germany: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.1.3 Germany: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.1.4 Germany: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.1.5 Germany: Vaccines Market Breakdown, by Influenza
    - 10.2.3.1.6 Germany: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.2 United Kingdom: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.2.1 United Kingdom: Vaccines Market Breakdown, by Technology
    - 10.2.3.2.2 United Kingdom: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.2.3 United Kingdom: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.2.4 United Kingdom: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.2.5 United Kingdom: Vaccines Market Breakdown, by Influenza
    - 10.2.3.2.6 United Kingdom: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.3 France: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.3.1 France: Vaccines Market Breakdown, by Technology
    - 10.2.3.3.2 France: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.3.3 France: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.3.4 France: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.3.5 France: Vaccines Market Breakdown, by Influenza
    - 10.2.3.3.6 France: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.4 Italy: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.4.1 Italy: Vaccines Market Breakdown, by Technology
    - 10.2.3.4.2 Italy: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.4.3 Italy: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.4.4 Italy: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.4.5 Italy: Vaccines Market Breakdown, by Influenza
    - 10.2.3.4.6 Italy: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.5 Spain: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.5.1 Spain: Vaccines Market Breakdown, by Technology
    - 10.2.3.5.2 Spain: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.5.3 Spain: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.5.4 Spain: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.5.5 Spain: Vaccines Market Breakdown, by Influenza
    - 10.2.3.5.6 Spain: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.6 Rest of Europe: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.6.1 Rest of Europe: Vaccines Market Breakdown, by Technology
    - 10.2.3.6.2 Rest of Europe: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.6.3 Rest of Europe: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.6.4 Rest of Europe: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.6.5 Rest of Europe: Vaccines Market Breakdown, by Influenza
    - 10.2.3.6.6 Rest of Europe: Vaccines Market Breakdown, by Route of Administration
10.3 Asia Pacific
- 10.3.1 Asia Pacific Vaccines Market Overview
- 10.3.2 Asia Pacific: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.3.2.1 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.3.2.2 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.3.2.3 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.3.2.4 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.3.2.5 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.3.2.6 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.3.3 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 China: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.1.1 China: Vaccines Market Breakdown, by Technology
    - 10.3.3.1.2 China: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.1.3 China: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.1.4 China: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.1.5 China: Vaccines Market Breakdown, by Influenza
    - 10.3.3.1.6 China: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.2 India: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.2.1 India: Vaccines Market Breakdown, by Technology
    - 10.3.3.2.2 India: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.2.3 India: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.2.4 India: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.2.5 India: Vaccines Market Breakdown, by Influenza
    - 10.3.3.2.6 India: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.3 Japan: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.3.1 Japan: Vaccines Market Breakdown, by Technology
    - 10.3.3.3.2 Japan: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.3.3 Japan: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.3.4 Japan: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.3.5 Japan: Vaccines Market Breakdown, by Influenza
    - 10.3.3.3.6 Japan: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.4 Australia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.4.1 Australia: Vaccines Market Breakdown, by Technology
    - 10.3.3.4.2 Australia: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.4.3 Australia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.4.4 Australia: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.4.5 Australia: Vaccines Market Breakdown, by Influenza
    - 10.3.3.4.6 Australia: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.5 South Korea: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.5.1 South Korea: Vaccines Market Breakdown, by Technology
    - 10.3.3.5.2 South Korea: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.5.3 South Korea: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.5.4 South Korea: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.5.5 South Korea: Vaccines Market Breakdown, by Influenza
    - 10.3.3.5.6 South Korea: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.6 Rest of APAC: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.6.1 Rest of APAC: Vaccines Market Breakdown, by Technology
    - 10.3.3.6.2 Rest of APAC: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.6.3 Rest of APAC: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.6.4 Rest of APAC: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.6.5 Rest of APAC: Vaccines Market Breakdown, by Influenza
    - 10.3.3.6.6 Rest of APAC: Vaccines Market Breakdown, by Route of Administration
10.4 Middle East and Africa
- 10.4.1 Middle East and Africa Vaccines Market Overview
- 10.4.2 Middle East and Africa: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.4.2.1 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.4.2.2 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.4.2.3 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.4.2.4 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.4.2.5 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.4.2.6 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.4.3 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 South Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.1.1 South Africa: Vaccines Market Breakdown, by Technology
    - 10.4.3.1.2 South Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.1.3 South Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.1.4 South Africa: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.1.5 South Africa: Vaccines Market Breakdown, by Influenza
    - 10.4.3.1.6 South Africa: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.2 Saudi Arabia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.2.1 Saudi Arabia: Vaccines Market Breakdown, by Technology
    - 10.4.3.2.2 Saudi Arabia: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.2.3 Saudi Arabia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.2.4 Saudi Arabia: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.2.5 Saudi Arabia: Vaccines Market Breakdown, by Influenza
    - 10.4.3.2.6 Saudi Arabia: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.3 United Arab Emirates: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.3.1 United Arab Emirates: Vaccines Market Breakdown, by Technology
    - 10.4.3.3.2 United Arab Emirates: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.3.3 United Arab Emirates: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.3.4 United Arab Emirates: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.3.5 United Arab Emirates: Vaccines Market Breakdown, by Influenza
    - 10.4.3.3.6 United Arab Emirates: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.4 Rest of Middle East and Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.4.1 Rest of Middle East and Africa: Vaccines Market Breakdown, by Technology
    - 10.4.3.4.2 Rest of Middle East and Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.4.3 Rest of Middle East and Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.4.4 Rest of Middle East and Africa: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.4.5 Rest of Middle East and Africa: Vaccines Market Breakdown, by Influenza
    - 10.4.3.4.6 Rest of Middle East and Africa: Vaccines Market Breakdown, by Route of Administration
10.5 South and Central America
- 10.5.1 South and Central America Vaccines Market Overview
- 10.5.2 South and Central America: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.5.2.1 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.5.2.2 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.5.2.3 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.5.2.4 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.5.2.5 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.5.2.6 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.5.3 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Brazil: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.1.1 Brazil: Vaccines Market Breakdown, by Technology
    - 10.5.3.1.2 Brazil: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.1.3 Brazil: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.1.4 Brazil: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.1.5 Brazil: Vaccines Market Breakdown, by Influenza
    - 10.5.3.1.6 Brazil: Vaccines Market Breakdown, by Route of Administration
  - 10.5.3.2 Argentina: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.2.1 Argentina: Vaccines Market Breakdown, by Technology
    - 10.5.3.2.2 Argentina: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.2.3 Argentina: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.2.4 Argentina: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.2.5 Argentina: Vaccines Market Breakdown, by Influenza
    - 10.5.3.2.6 Argentina: Vaccines Market Breakdown, by Route of Administration
  - 10.5.3.3 Rest of South and Central America: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.3.1 Rest of South and Central America: Vaccines Market Breakdown, by Technology
    - 10.5.3.3.2 Rest of South and Central America: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.3.3 Rest of South and Central America: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.3.4 Rest of South and Central America: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.3.5 Rest of South and Central America: Vaccines Market Breakdown, by Influenza
    - 10.5.3.3.6 Rest of South and Central America: Vaccines Market Breakdown, by Route of Administration

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Ranking by Key Players

14. Vaccines Market - Key Company Profiles

14.1 GlaxoSmithKline plc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Merck and Co., Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Serum Institute of India (SII)
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 BioNTech
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Abbott
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Sinovac
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Novartis
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 CSL Seqirus
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud